Buy AbbVie on Immunology Momentum; Play for Mid-Term Upside from Pipeline and Re-rating
AbbVie is pivoting from Humira dependency toward a high-growth immunology franchise led by Skyrizi and Rinvoq, with an emerging oncology pipeline that could provide upside. Trailing multiples look stretched, but forward guidance implies a much more attractive valuation. This trade plan buys the current strength with a defined stop and a mid-term ti…